Slide 1: 1H FY26 Presentation
1H FY26 Presentation 26 February 2026
Slide 2: Genetic Signatures Limited (GSS.ASX) Company Bio Summary
Genetic Signatures Limited (GSS.ASX) Company Bio Summary Business Operations Products & Services Strategy & Growth • Genetic Signatures is a ASX molecular • The company specialises in PCR Delivering on our Strategy to achieve our Growth diagnostics company headquartered in (Polymerase Chain Reaction
Slide 3: Summary: 1H FY26 Operating Update
Summary 1H FY26 Operating Update 01 02 03 04 05 Australia USA EMEA Reviews Key Management Changes Maintained revenue First revenue Focus on utilising the Forensic review of Leadership change of base in Australia recognised in key growing base of operational and financial CEO to Maria Halasz market w
Slide 4: Financials
September 2023 Financials Financials 1H FY26 Results
Slide 5: Key Financial Metrics
Key Financial Metrics 1H FY26 Snapshot Revenue Gross Profit Gross Margin Up 2.4% to Down 4.0% to Down 3.1% to $8.7m $4.8m 55.7% (1H FY25 $8.5m) (1H FY25 $5.0m) (1H FY25 58.8%) Und. Operating Loss Cash & Equivalents Net Assets Improved 23.8% to Down $1.4m Declined $6.0m $6.4m $29.9 $44.1m (1H FY25 $8
Slide 6: 1H FY26 Highlights
1H FY26 Highlights Key Financial Metrics Total Revenue Gross Profit & Margin Underlying NPBT Cash & Equivalents • Revenue of $8.7m vs $8.5m • Gross Profit margin decline of • Underlying NPBT Loss of • Cash & cash equivalents of pcp, with steady sales in $4.8m vs $5.0m, due to $6.4m vs a loss of $8.4
Slide 7: Outlook
Genetic Signatures Transforming Molecular Diagnostics Outlook 1H FY26 Results
Slide 8: FY26 2H Outlook
FY26 2H Outlook • Expect Australia to remain steady 1 Revenue • Focus on continued growth in the US and EMEA to become a more diversified business • Focus on increasing awareness of the advantages of 3base technology and continuing to build out 2 Product customer base with existing products • Identi
Slide 9: Appendix
Genetic Signatures Transforming Molecular Diagnostics Appendix
Slide 10: Income Statement
Income Statement Improving Revenue & Declining operating Loss in 1H FY26 A$m 1H FY26 1H FY25 $ Change • Revenue of $8.7m vs $8.5m, an increase of +2.3% vs Total Revenue 8.7 8.5 0.2 pcp. Sales growth attributable to increasing respiratory (-) Cost of Goods Sold (3.9) (3.5) (0.4) diagnostic sales volu
Slide 11: Balance Sheet
Balance Sheet Balance Sheet Stable A$m Dec ‘25 Jun ‘25 $ Change Current Assets Cash 17.2 7.5 9.7 • As at 31 December 2025, Genetic Signatures held total Financial Assets 12.7 23.8 (11.1) cash of $29.9m, comprising $17.2m in cash at bank and Receivables 2.7 3.4 (0.7) $12.7m in term deposits Inventory
Slide 12: Cashflow Statement
Cashflow Statement Disciplined Cash Usage A$m 1H FY26 1H FY25 $ Change • Cash receipts of $10.2m vs $10.3m pcp, remains Cash Receipts 10.2 10.3 (0.1) steady, attributable largely to Australian customers (-) Cash Paid to Suppliers (15.6) (18.8) 3.2 (+) Net Interest Received 0.7 0.5 0.2 • Cash Paid to
Slide 13: Disclaimer
1H FY26 Presentation 26 February 2026 Disclaimer This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It provides general background information about the Company’s activities current as at the date